<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118061</url>
  </required_header>
  <id_info>
    <org_study_id>NB21-SSK-NA-FDA</org_study_id>
    <nct_id>NCT05118061</nct_id>
  </id_info>
  <brief_title>StatStrip Glucose/Ketone Meter System Ketone Evaluation</brief_title>
  <official_title>StatStrip Glucose/Ketone Meter System Ketone Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Florida Research Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technical University of Munich - Diabetes Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technical University of Munich - Emergency Reception</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Nova StatStrip Glucose / Ketone Meter System is a fast, simple, whole blood system that&#xD;
      can be used to quantify both glucose and ketones using two distinct test strips. This&#xD;
      Protocol will describe an evaluation of the system's Ketone performance only. Ketone testing&#xD;
      methods that quantify beta-hydroxybutyrate (β-OHB), the predominant ketone body, are used for&#xD;
      diagnosing and monitoring ketoacidosis, a life-threatening complication of hyperglycemia. The&#xD;
      performance of the StatStrip Ketone test strip using the Nova StatStrip Glucose / Ketone&#xD;
      Hospital Meter System on venous and capillary whole blood will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are:&#xD;
&#xD;
        1. To assess the performance of the StatStrip Ketone assay in the hands of CLIA-Waived&#xD;
           Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on&#xD;
           venous, and capillary blood and compare the performance characteristics to a traceable&#xD;
           laboratory reference method.&#xD;
&#xD;
        2. To assess the Ease of Use of the StatStrip Glucose / Ketone Meter System in the hands of&#xD;
           the intended CLIA-Waived Point-of-Care users. CLIA-Waived operators will be provided&#xD;
           with all package-insert sheets, a Quick Reference Guide and Instructions for Use (IFU)&#xD;
           Manual. No training, coaching, or prompting will be provided to the CLIA-Waived POC&#xD;
           Users other than clarifying the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analytical verification of StatStrip glucose/ketone meter system - ketone comparison</measure>
    <time_frame>20 days</time_frame>
    <description>StatStrip ketone meter system, a point of care testing instrument is as effective as a reference laboratory method for ketone results in mmol/L</description>
  </primary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Ketosis, Diabetic</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ketone</intervention_name>
    <description>compare diagnostic tests to reference methods</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        a minimum of 360 to a maximum of 500 individual subjects will be enrolled to test both&#xD;
        capillary and venous whole blood. Subjects included in the study may be healthy, diabetic&#xD;
        or suspected of ketonemia. The study will be conducted in at least three (3) separate study&#xD;
        sites, with each site targeting 120 patients up to 200 patients.&#xD;
&#xD;
        Adult subjects (≥ 18 years old) of both genders will be included in this study.&#xD;
&#xD;
        Potential subjects may be screened prior to testing to assess their baseline ketone levels.&#xD;
        The screening may be done by inspecting medical records, fingerstick ketone testing or&#xD;
        urine dipstick testing. Each site shall follow their own specified procedures and protocols&#xD;
        for the screening test method, if applicable.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult subjects (≥ 18 years old) with diabetes or suspected ketonemia.&#xD;
&#xD;
          2. Adult subjects (≥ 18 years old) that are healthy.&#xD;
&#xD;
          3. Subjects willing and able to consent to participating in the study.&#xD;
&#xD;
          4. Subjects whose pre-screen ketone value, if performed, is deemed valuable to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects unable to consent to participating in the study.&#xD;
&#xD;
          2. Subjects possessing a cognitive disorder or other condition, which, in the opinion of&#xD;
             the investigator, would put the person at risk or seriously compromise the integrity&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Bleicher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Florida Research Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Luppa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Munich - Diabetes Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Luppa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Munich - Emergency Reception</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarrid Legere, Bachelor</last_name>
    <phone>781-894-0800</phone>
    <phone_ext>1801</phone_ext>
    <email>jlegere@novabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Qiu, Md, PhD</last_name>
    <phone>781-894-0800</phone>
    <phone_ext>1715</phone_ext>
    <email>wqiu@novabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Florida Research Organization</name>
      <address>
        <city>Medley</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Bleicher</last_name>
      <phone>850-658-8059</phone>
      <email>bleicher.sfro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich - Diabetes Hospital</name>
      <address>
        <city>Munich</city>
        <zip>D-80333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Luppa</last_name>
      <phone>+49-89-4140759</phone>
      <email>p.luppa@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technical University of Munich - Emergency Reception</name>
      <address>
        <city>Munich</city>
        <zip>D-80333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Luppa</last_name>
      <phone>+49-89-4140759</phone>
      <email>p.luppa@tum.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

